The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Brian Cheng - JPMorgan Chase & Co - Analyst
: Hey guys, can you hear me?
Question: Brian Cheng - JPMorgan Chase & Co - Analyst
: Brian. Well, thanks for taking our questions here. A couple from us. Just want to pick your brain a bit on the setup for the Phase I/IIa trial.
What do you want to see across the three doses in the MAD portion that you've selected for hair counts and also hair width? And then we
have a quick follow-up.
Question: Brian Cheng - JPMorgan Chase & Co - Analyst
: And then if I can just add one more. Just on the subcu versus IV dose formulation here, how should we think of the subcu dose range in
relationship to the IV doses that you have selected?
LSEG STREETEVENTS | www.lseg.com | Contact Us
consent of LSEG. 'LSEG' and the LSEG logo are registered trademarks of LSEG and its affiliated companies.
Question: Brian Cheng - JPMorgan Chase & Co - Analyst
: Great, thank you guys.
Question: Debanjana Chatterjee - Jonestrading Institutional Services LLC - Analyst
: Hi. Do you guys hear me? Thanks for the exciting presentation. So can you please confirm if the ex-vivo experiments were performed on
hair follicles from healthy male donors. And if so, how do you think the findings would translate into like patients with established AGA? And
I have a commercial follow-up.
Question: Debanjana Chatterjee - Jonestrading Institutional Services LLC - Analyst
: Yes. And maybe thinking about the commercial --
LSEG STREETEVENTS | www.lseg.com | Contact Us
consent of LSEG. 'LSEG' and the LSEG logo are registered trademarks of LSEG and its affiliated companies.
Question: Debanjana Chatterjee - Jonestrading Institutional Services LLC - Analyst
: Great. And are there any additional hair loss conditions where you think modulating the prolactin signal could offer therapeutic benefit
outside of AGA?
Question: Debanjana Chatterjee - Jonestrading Institutional Services LLC - Analyst
: Very helpful. Thank you. I'll hop back in the queue.
Question: Debanjana Chatterjee - Jonestrading Institutional Services LLC - Analyst
: Great. Thanks for all the additional color, very useful context. Thank you.
LSEG STREETEVENTS | www.lseg.com | Contact Us
consent of LSEG. 'LSEG' and the LSEG logo are registered trademarks of LSEG and its affiliated companies.
Question: Morgan Gryga - Morgan Stanley - Analyst
: Hi, everyone. Thanks. I'm calling in for Sean Laaman. So we've seen in preclinical studies for ABS-201 potential re-pigmentation effects too.
How could that present potential upside for ABS-201 in this market?
Question: Charles Wallace, Ph.D. - H C Wainwright & Co LLC (Pre-Merger) - Analyst
: Hi. Thanks for a great presentation. And a little bit of color, if I may, on the HEADLINE Phase IIa design, regarding later clinical development,
would you need to do an additional -- or what additional trials would you need to do? Would you go into a Phase IIb or directly into a Phase
III? And then also, is there a precedence to keep males and females in separate cohorts or even separate studies?
Question: Charles Wallace, Ph.D. - H C Wainwright & Co LLC (Pre-Merger) - Analyst
: Great. And then a follow-up, if I may. So on the proof-of-concept data that's coming out, what differences should we expect to see between
the 13 weeks and at 26 weeks? And then also on this, would we get any idea of the potential re-pigmentation from these readouts?
Question: Charles Wallace, Ph.D. - H C Wainwright & Co LLC (Pre-Merger) - Analyst
: Great. Yes. I know my mom would be one of your first customers if that's the case.
LSEG STREETEVENTS | www.lseg.com | Contact Us
consent of LSEG. 'LSEG' and the LSEG logo are registered trademarks of LSEG and its affiliated companies.
Question: Charles Wallace, Ph.D. - H C Wainwright & Co LLC (Pre-Merger) - Analyst
: Great. Thank you, guys.
Question: Anna Li - Truist Securities - Analyst
: Can you guys hear me?
Question: Anna Li - Truist Securities - Analyst
: This is Anna on for Kripa. Thanks for the question. For Dr. Sinclair, one question. Besides the dose selection, could you also talk about any
Question: Anna Li - Truist Securities - Analyst
: And any expectations for kind of that safety SAD readout besides kind of looking at half-life, any potential safety concerns? I know there's
like some theoretical concerns of prolactin suppression with like immune bone loss, anything like that?
Question: Anna Li - Truist Securities - Analyst
: Thank you so much.
| 
